Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.
作者信息
Zeidan Amer M, Stahl Maximilian, Hu Xin, Wang Rong, Huntington Scott F, Podoltsev Nikolai A, Gore Steven D, Ma Xiaomei, Davidoff Amy J
机构信息
Department of Internal Medicine, School of Medicine.
Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale University School of Medicine.
出版信息
Blood. 2018 Feb 15;131(7):818-821. doi: 10.1182/blood-2017-10-811729. Epub 2017 Dec 19.
Abstract
摘要
相似文献
1
Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.接受HMA治疗且未进行后续干细胞移植的老年骨髓增生异常综合征患者的长期生存情况。
Blood. 2018 Feb 15;131(7):818-821. doi: 10.1182/blood-2017-10-811729. Epub 2017 Dec 19.
2
Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study.5 天地西他滨与 7 天地阿扎胞苷治疗伴有不良预后特征的低危骨髓增生异常综合征的比较：一项回顾性多中心队列研究。
Sci Rep. 2020 Jan 8;10(1):39. doi: 10.1038/s41598-019-56642-1.
3
No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.与支持性治疗相比，低甲基化药物治疗高危骨髓增生异常综合征没有获益。
Korean J Intern Med. 2018 Nov;33(6):1194-1202. doi: 10.3904/kjim.2016.426. Epub 2017 Dec 15.
4
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.经去甲基化药物治疗后的骨髓增生异常综合征中的造血细胞移植
Biol Blood Marrow Transplant. 2017 Sep;23(9):1509-1514. doi: 10.1016/j.bbmt.2017.05.034. Epub 2017 Jun 30.
5
Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience.低甲基化药物（HMAs）对无法分类的骨髓增生异常/骨髓增殖性肿瘤（MDS/MPN-U）的影响：单机构经验
Leuk Lymphoma. 2018 Nov;59(11):2737-2739. doi: 10.1080/10428194.2018.1436705. Epub 2018 Feb 21.
6
Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.地西他滨分别联合复杂核型治疗急性髓系白血病和骨髓增生异常综合征。
Asian Pac J Cancer Prev. 2015;16(15):6627-32. doi: 10.7314/apjcp.2015.16.15.6627.
7
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.异基因造血干细胞移植后髓系恶性肿瘤复发的治疗：维奈托克联合低甲基化药物的回顾性多中心分析-代表德国合作移植研究组。
Ann Hematol. 2021 Apr;100(4):959-968. doi: 10.1007/s00277-020-04321-x. Epub 2020 Nov 16.
8
Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response.使用去甲基化药物（HMAs）治疗后的骨髓增生异常综合征：急性红白血病的发生可能不影响治疗反应的评估。
Leuk Lymphoma. 2016;57(4):812-9. doi: 10.3109/10428194.2015.1079318. Epub 2016 Mar 4.
9
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.来那度胺和低甲基化药物的治疗顺序及其对骨髓增生异常综合征患者临床结局的影响。
Leuk Lymphoma. 2019 Aug;60(8):2050-2055. doi: 10.1080/10428194.2018.1551538. Epub 2019 Jan 14.
10
Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.靶向急性髓系白血病和骨髓增生异常综合征中的表观遗传途径：对去甲基化药物试验的系统评价
Clin Epigenetics. 2016 Jun 14;8:68. doi: 10.1186/s13148-016-0233-2. eCollection 2016.
引用本文的文献
1
Checkpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4 T cells in MDS.检查点免疫疗法与骨髓增生异常综合征（MDS）中肿瘤抗原特异性CD4 T细胞的优先激活相关。
Blood Neoplasia. 2025 Apr 25;2(3):100106. doi: 10.1016/j.bneo.2025.100106. eCollection 2025 Aug.
2
Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches.超越去甲基化药物：新型疗法与靶向治疗方法
Clin Hematol Int. 2025 Aug 7;7(3):24-35. doi: 10.46989/001c.142956. eCollection 2025.
3
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.降低骨髓增生异常综合征患者临床试验的入选障碍：一份国际骨髓增生异常综合征工作组立场声明
Blood. 2025 Mar 27;145(13):1369-1381. doi: 10.1182/blood.2023023717.
4
Integrating advanced analytical methods to assess epigenetic marks affecting response to hypomethylating agents in higher risk myelodysplastic syndrome.整合先进分析方法以评估影响高危骨髓增生异常综合征对去甲基化药物反应的表观遗传标记。
Mol Med. 2025 Feb 14;31(1):59. doi: 10.1186/s10020-025-01123-7.
5
Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives.骨髓增生异常综合征（MDS）中的可测量（微小）残留病：现状与展望
Cancers (Basel). 2024 Apr 15;16(8):1503. doi: 10.3390/cancers16081503.
6
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.老年骨髓增生异常综合征的治疗：科学现状、挑战与机遇。
Curr Hematol Malig Rep. 2024 Jun;19(3):138-150. doi: 10.1007/s11899-024-00733-y. Epub 2024 Apr 18.
7
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.一项多中心 Ib 期临床试验，评估组蛋白去乙酰化酶抑制剂恩替诺特与帕博利珠单抗联合用于对低甲基化药物难治的骨髓增生异常综合征/肿瘤或急性髓系白血病患者的疗效。
Ann Hematol. 2024 Jan;103(1):105-116. doi: 10.1007/s00277-023-05552-4. Epub 2023 Dec 1.
8
Are We Ready For "Triplet" Therapy in Higher-Risk MDS?我们是否准备好对高危骨髓增生异常综合征进行“三联”治疗？
Clin Hematol Int. 2023 Nov 3;5(4):88301. doi: 10.46989/001c.88301. eCollection 2023.
9
A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data.利用真实世界数据的机器学习模型识别的骨髓增生异常综合征和其他髓系肿瘤中阿扎胞苷治疗结果的个性化风险模型。
Cancers (Basel). 2023 Aug 8;15(16):4019. doi: 10.3390/cancers15164019.
10
What's Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach.骨髓肿瘤中去甲基化药物治疗失败后下一步该怎么做？一种合理的方法。
Cancers (Basel). 2023 Apr 12;15(8):2248. doi: 10.3390/cancers15082248.
本文引用的文献
1
A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.行动呼吁：增加未经治疗的高危骨髓增生异常综合征患者在一线临床试验中的入组率。
Cancer. 2017 Oct 1;123(19):3662-3672. doi: 10.1002/cncr.30903. Epub 2017 Jul 31.
2
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.阿扎胞苷与地西他滨治疗老年骨髓增生异常综合征患者的临床疗效比较
Br J Haematol. 2016 Dec;175(5):829-840. doi: 10.1111/bjh.14305. Epub 2016 Sep 21.
3
Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States.在美国低甲基化药物时代，伴有过多原始细胞的难治性贫血患者的生存率有适度提高。
Leuk Lymphoma. 2017 Apr;58(4):982-985. doi: 10.1080/10428194.2016.1214954. Epub 2016 Aug 25.
4
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.用于预测接受氮杂核苷治疗的高危骨髓增生异常综合征患者预后的风险分层工具比较
Leukemia. 2016 Mar;30(3):649-57. doi: 10.1038/leu.2015.283. Epub 2015 Oct 14.
5
Myelodysplastic Syndromes: Diagnosis and Treatment.骨髓增生异常综合征：诊断与治疗
Mayo Clin Proc. 2015 Jul;90(7):969-83. doi: 10.1016/j.mayocp.2015.04.001.
6
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.阿扎胞苷治疗未选择高危骨髓增生异常综合征的疗效：来自西班牙登记处的数据。
Leukemia. 2015 Sep;29(9):1875-81. doi: 10.1038/leu.2015.115. Epub 2015 May 6.
7
Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights.谁能从异基因移植治疗骨髓增生异常综合征中获益？新见解。
Hematology Am Soc Hematol Educ Program. 2013;2013:522-8. doi: 10.1182/asheducation-2013.1.522.
8
Current therapy of myelodysplastic syndromes.骨髓增生异常综合征的当前治疗。
Blood Rev. 2013 Sep;27(5):243-59. doi: 10.1016/j.blre.2013.07.003. Epub 2013 Jul 27.
9
Underreporting of myeloid malignancies by United States cancer registries.美国癌症登记处对髓系恶性肿瘤的漏报。
Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):474-81. doi: 10.1158/1055-9965.EPI-11-1087. Epub 2012 Jan 11.
10
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.在 282 例接受阿扎胞苷治疗的高危骨髓增生异常综合征患者中，预测反应和总生存的预后因素。
Blood. 2011 Jan 13;117(2):403-11. doi: 10.1182/blood-2010-06-289280. Epub 2010 Oct 12.
Zotero 插件